You have 9 free searches left this month | for more free features.

renal adenocarcinoma

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer Trial

Not yet recruiting
  • Clear Cell Renal Cell Carcinoma
  • +2 more
  • (no location specified)
May 14, 2023

Advanced Solid Tumors, Solid Tumor, Solid Carcinoma Trial (Belzutifan)

Active, not recruiting
  • Advanced Solid Tumors
  • +15 more
  • (no location specified)
Sep 16, 2022

ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer Trial (NKT2152, palbociclib, sasanlimab)

Not yet recruiting
  • ccRCC
  • +20 more
  • (no location specified)
Jul 6, 2023

Renal Cell Carcinoma, NSCLC, Pancreatic Adenocarcinoma, Colorectal Cancer Trial (RO7515629, tocilizumab)

Not yet recruiting
  • Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer
  • (no location specified)
Mar 3, 2023

Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma Trial in London (Savolitinib, MEDI4736, Tremelimumab)

Active, not recruiting
  • Renal Clear Cell Carcinoma
  • Renal Papillary Cell Carcinoma
  • London, United Kingdom
    Thomas Powles
Aug 10, 2022

Pancreatic Adenocarcinoma Non-resectable, Pancreatic Adenocarcinoma Metastatic, Colorectal Cancer Metastatic Trial in New York

Completed
  • Pancreatic Adenocarcinoma Non-resectable
  • +2 more
  • RENCA macrobeads
  • New York, New York
    Weill Cornell Medical Center / The Rogosin Institute
Apr 23, 2021

Advanced Solid Tumor, CDKN2A, NSCLC Trial (Milademetan, Atezolizumab)

Withdrawn
  • Advanced Solid Tumor
  • +9 more
  • (no location specified)
Oct 16, 2023

ResiduAl Cancer With Liquid Biopsy Evaluation

Recruiting
  • Bladder Carcinoma
  • +14 more
  • Guardant Reveal
  • Redwood City, California
    Redwood City
Sep 7, 2022

Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) Trial (KO-2806, Cabozantinib)

Not yet recruiting
  • Solid Tumors With HRAS Alterations
  • +4 more
  • (no location specified)
Aug 30, 2023

Kidney Cancer, Renal Cell Carcinoma, Clear Cell Carcinoma Trial in Dallas (13C-Glucose, 13C-Acetate, 13C-Lactate)

Recruiting
  • Kidney Cancer
  • +11 more
  • 13C-Glucose
  • +4 more
  • Dallas, Texas
    University of Texas Southwestern Medical Center
Dec 1, 2022

Prostate Cancer, Breast Cancer, Kidney Cancer Trial in Tampere (behavioral, drug, other)

Not yet recruiting
  • Prostate Cancer
  • +11 more
  • Guided physical exercise
  • +2 more
  • Tampere, Länsi-Suomi, Finland
    Tampere University Hospital
Apr 3, 2023

Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma Trial in Nashville (CTX131)

Recruiting
  • Clear Cell Renal Cell Carcinoma
  • +4 more
  • CTX131
  • Nashville, Tennessee
    Research Site 1
Mar 21, 2023

Colorectal Cancers Trial in United States (RENCA macrobeads)

Completed
  • Colorectal Cancers
  • RENCA macrobeads
  • Westwood, Kansas
  • +3 more
Feb 25, 2021

Metastatic Solid Tumors, NSCLC, Melanoma Trial in United States (INBRX-105 - PDL1x41BB antibody, Pembrolizumab)

Recruiting
  • Metastatic Solid Tumors
  • +7 more
  • Scottsdale, Arizona
  • +12 more
Jan 26, 2023

Multimodal Machine Learning Characterization of Solid Tumors

Recruiting
  • Adenocarcinoma of Prostate
  • +5 more
  • Boston, Massachusetts
  • +1 more
Apr 4, 2022

Advanced Clear Cell Renal Cell Carcinoma, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Infiltrating Bladder

Active, not recruiting
  • Advanced Clear Cell Renal Cell Carcinoma
  • +35 more
  • Cabozantinib S-malate
  • +2 more
  • Duarte, California
  • +7 more
Jan 3, 2023

Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma Trial in United Kingdom, United States

Terminated
  • Pancreatic Adenocarcinoma
  • +13 more
  • San Francisco, California
  • +7 more
Aug 17, 2022

Adenocarcinoma, Prostate Tumors, Prostate Cancer Trial run by the National Institutes of Health Clinical Center (CC) (EM

Enrolling by invitation
  • Adenocarcinoma
  • +4 more
  • EM Tracking
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Apr 7, 2022

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8

Recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +129 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
Apr 8, 2022

Triple Negative Breast Cancer, Renal Cell Cancer, High Grade Ovarian Serous Adenocarcinoma Trial in United Kingdom

Recruiting
  • Triple Negative Breast Cancer
  • +3 more
  • Modi-1/Modi-1v
  • +2 more
  • Brighton, Default, United Kingdom
  • +13 more
Nov 18, 2022

Remote Telemonitoring of Patient-Generated Physiologic Health

Recruiting
  • Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8
  • +171 more
  • Patient Monitoring
  • Questionnaire Administration
  • Duarte, California
    City of Hope Medical Center
Aug 15, 2022

ID TCRs From Renal Clear Cell Carcinoma Patients Responding to

Withdrawn
  • Renal Clear Cell Carcinoma
    • Saint Louis, Missouri
      Washington University School of Medicine
    Aug 19, 2021

    Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Tumor Trial in Atlanta (procedure,

    Not yet recruiting
    • Bladder Squamous Cell Carcinoma
    • +10 more
    • Biospecimen Collection
    • +5 more
    • Atlanta, Georgia
    • +3 more
    Feb 20, 2023